000148292 001__ 148292
000148292 005__ 20240229123030.0
000148292 0247_ $$2doi$$a10.1007/s11060-019-03348-z
000148292 0247_ $$2pmid$$apmid:31776900
000148292 0247_ $$2ISSN$$a0167-594X
000148292 0247_ $$2ISSN$$a0167-594x
000148292 0247_ $$2ISSN$$a1573-7373
000148292 0247_ $$2altmetric$$aaltmetric:71412119
000148292 037__ $$aDKFZ-2019-02856
000148292 041__ $$aeng
000148292 082__ $$a610
000148292 1001_ $$0P:(DE-HGF)0$$aBerberich, Anne$$b0$$eFirst author
000148292 245__ $$acMyc and ERK activity are associated with resistance to ALK inhibitory treatment in glioblastoma.
000148292 260__ $$aDordrecht [u.a.]$$bSpringer Science + Business Media B.V$$c2020
000148292 3367_ $$2DRIVER$$aarticle
000148292 3367_ $$2DataCite$$aOutput Types/Journal article
000148292 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1601365815_28064
000148292 3367_ $$2BibTeX$$aARTICLE
000148292 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000148292 3367_ $$00$$2EndNote$$aJournal Article
000148292 500__ $$a2020 Jan;146(1):9-23#EA:B320#LA:B320#
000148292 520__ $$aAnaplastic lymphoma kinase (ALK) is expressed in ~ 60% of glioblastomas and conveys tumorigenic functions. Therefore, ALK inhibitory strategies with alectinib are conceivable for patients with glioblastoma. The aims of this preclinical study were to investigate efficacy as well as to understand and potentially overcome primary and acquired resistance mechanisms of alectinib in glioblastoma.Efficacy of alectinib was analyzed dependent on ALK expression in different glioblastoma initiating cells and after lentiviral knockdown of ALK. Alectinib resistant cells were generated by continuous treatment with increasing alectinib doses over 3 months. M-RNA, phospho-protein and protein regulation were analyzed to decipher relevant pathways associated to treatment or resistance and specifically inhibited to evaluate rational salvage therapies.Alectinib reduced clonogenicity and proliferation and induced apoptosis in ALK expressing glioblastoma initiating cells, whereas cells without ALK expression or after ALK depletion via knockdown showed primary resistance against alectinib. High expression of cMyc and activation of the ERK1/2 pathway conferred resistance against alectinib in ALK expressing glioblastoma cells. Pharmacological inhibition of these pathways by cMyc inhibitor or MEK inhibitor, trametinib, overcame alectinib resistance and re-sensitized resistant cells to continued alectinib treatment. The combination of alectinib with radiotherapy demonstrated synergistic effects in inhibition of clonogenicity in non-resistant and alectinib resistant glioblastoma cells.The data offer rationales for alectinib treatment in ALK expressing glioblastoma and for the use of ALK expression status as potential biomarker for alectinib treatment. In addition, the results propose MEK inhibition or radiotherapy as reasonable salvage treatments after acquired alectinib resistance.
000148292 536__ $$0G:(DE-HGF)POF3-312$$a312 - Functional and structural genomics (POF3-312)$$cPOF3-312$$fPOF III$$x0
000148292 588__ $$aDataset connected to CrossRef, PubMed,
000148292 7001_ $$0P:(DE-He78)150ba0b357f126058b563bcbfd6d43dd$$aSchmitt, Lara-Marie$$b1
000148292 7001_ $$0P:(DE-He78)f2efee17b6ca2f790176a2c036912536$$aPusch, Stefan$$b2$$udkfz
000148292 7001_ $$0P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f$$aHielscher, Thomas$$b3$$udkfz
000148292 7001_ $$0P:(DE-He78)4a2920bbf698256b49daaed4bcbd263c$$aRübmann, Petra$$b4$$udkfz
000148292 7001_ $$0P:(DE-He78)f22b88c550ade8d906f161dde4fadd00$$aHucke, Nanina$$b5
000148292 7001_ $$0P:(DE-He78)b57f38e35667835ffe722d1837c4937b$$aLatzer, Pauline$$b6$$udkfz
000148292 7001_ $$0P:(DE-He78)a5f5be3a0458fbc0017086b569fe7d75$$aHeßling, Bernd$$b7$$udkfz
000148292 7001_ $$0P:(DE-He78)71cda0dea83ffa671c1d3b2f6e847ead$$aLemke, Dieter$$b8$$udkfz
000148292 7001_ $$0P:(DE-He78)5c2c9cbe6ce72553684d82d94aebdadd$$aKessler, Tobias$$b9$$udkfz
000148292 7001_ $$0P:(DE-He78)5ef8651b0f857b9c640aa5b1498c43b5$$aPlatten, Michael$$b10$$udkfz
000148292 7001_ $$0P:(DE-He78)92e9783ca7025f36ce14e12cd348d2ee$$aWick, Wolfgang$$b11$$eLast author$$udkfz
000148292 773__ $$0PERI:(DE-600)2007293-4$$a10.1007/s11060-019-03348-z$$n1$$p9-23$$tJournal of neuro-oncology$$v146$$x1573-7373$$y2020
000148292 909CO $$ooai:inrepo02.dkfz.de:148292$$pVDB
000148292 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000148292 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)150ba0b357f126058b563bcbfd6d43dd$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000148292 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f2efee17b6ca2f790176a2c036912536$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000148292 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000148292 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4a2920bbf698256b49daaed4bcbd263c$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000148292 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f22b88c550ade8d906f161dde4fadd00$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000148292 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b57f38e35667835ffe722d1837c4937b$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000148292 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a5f5be3a0458fbc0017086b569fe7d75$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000148292 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)71cda0dea83ffa671c1d3b2f6e847ead$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000148292 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)5c2c9cbe6ce72553684d82d94aebdadd$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000148292 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)5ef8651b0f857b9c640aa5b1498c43b5$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000148292 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)92e9783ca7025f36ce14e12cd348d2ee$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000148292 9131_ $$0G:(DE-HGF)POF3-312$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunctional and structural genomics$$x0
000148292 9141_ $$y2020
000148292 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000148292 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ NEURO-ONCOL : 2017
000148292 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000148292 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000148292 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000148292 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000148292 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000148292 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000148292 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000148292 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000148292 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000148292 9202_ $$0I:(DE-He78)B320-20160331$$kB320$$lKKE Neuroonkologie$$x0
000148292 9200_ $$0I:(DE-He78)B320-20160331$$kB320$$lKKE Neuroonkologie$$x0
000148292 9201_ $$0I:(DE-He78)B320-20160331$$kB320$$lKKE Neuroonkologie$$x0
000148292 9201_ $$0I:(DE-He78)B300-20160331$$kB300$$lKKE Neuropathologie$$x1
000148292 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lC060 Biostatistik$$x2
000148292 9201_ $$0I:(DE-He78)W120-20160331$$kW120$$lW120 Proteinanalyse$$x3
000148292 9201_ $$0I:(DE-He78)D170-20160331$$kD170$$lNeuroimmunologie und Hirntumorimmunologie$$x4
000148292 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x5
000148292 980__ $$ajournal
000148292 980__ $$aVDB
000148292 980__ $$aI:(DE-He78)B320-20160331
000148292 980__ $$aI:(DE-He78)B300-20160331
000148292 980__ $$aI:(DE-He78)C060-20160331
000148292 980__ $$aI:(DE-He78)W120-20160331
000148292 980__ $$aI:(DE-He78)D170-20160331
000148292 980__ $$aI:(DE-He78)HD01-20160331
000148292 980__ $$aUNRESTRICTED